Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized Placebo-controlled Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory Epileptic Crisis in Children and Adolescents

NCT02783092 is registered in ClinicalTrials.gov with Antonio Waldo Zuardi as lead sponsor.

NCT NCT02783092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02783092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized Placebo-controlled Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory Epileptic Crisis in Children and Adolescents
Lead sponsor
Antonio Waldo Zuardi
Phase
Phase 3
Overall status
Unknown status
Start date
January 9, 2019
Completion date
September 25, 2024
Enrollment
126 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy